RetroSearch Browse

Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/32838355/ below:

Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19

. 2020 Dec 18;1(1):114-127.e3. doi: 10.1016/j.medj.2020.06.001. Epub 2020 Jun 5. Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19

Affiliations

¹ Dorn Research Institute, Columbia VA Health Care System, Columbia, SC, USA.
² Department of Clinical Pharmacy & Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, USA.
³ Center for Advanced Vision Science, University of Virginia School of Medicine, Charlottesville, VA, USA.
⁴ Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA, USA.
⁵ Department of Epidemiology & Biostatistics, University of South Carolina, Columbia, SC, USA.
⁶ Department of Pathology, University of Virginia School of Medicine, Charlottesville, VA, USA.
⁷ Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, VA, USA.

PMID: 32838355
PMCID: PMC7274588
DOI: 10.1016/j.medj.2020.06.001

Item in Clipboard

Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19

Joseph Magagnoli et al. Med. 2020.

. 2020 Dec 18;1(1):114-127.e3. doi: 10.1016/j.medj.2020.06.001. Epub 2020 Jun 5. Affiliations

¹ Dorn Research Institute, Columbia VA Health Care System, Columbia, SC, USA.
² Department of Clinical Pharmacy & Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, USA.
³ Center for Advanced Vision Science, University of Virginia School of Medicine, Charlottesville, VA, USA.
⁴ Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA, USA.
⁵ Department of Epidemiology & Biostatistics, University of South Carolina, Columbia, SC, USA.
⁶ Department of Pathology, University of Virginia School of Medicine, Charlottesville, VA, USA.
⁷ Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, VA, USA.

PMID: 32838355
PMCID: PMC7274588
DOI: 10.1016/j.medj.2020.06.001

Item in Clipboard

Abstract

Background: Despite limited and conflicting evidence, hydroxychloroquine, alone or in combination with azithromycin, is widely used in COVID-19 therapy.

Methods: We performed a retrospective study of electronic health records of patients hospitalized with confirmed SARS-CoV-2 infection in US Veterans Health Administration medical centers between March 9, 2020 and April 29, 2020. Patients hospitalized within 24 h of diagnosis were classified based on their exposure to hydroxychloroquine alone (HC) or with azithromycin (HC+AZ) or no HC as treatments. The primary outcomes were mortality and use of mechanical ventilation.

Findings: A total of 807 patients were evaluated. Compared to the no HC group, after propensity score adjustment for clinical characteristics, the risk of death from any cause was higher in the HC group (adjusted hazard ratio [aHR], 1.83; 95% confidence interval [CI], 1.16-2.89; p = 0.009), but not in the HC+AZ group (aHR, 1.31; 95% CI, 0.80-2.15; p = 0.28). Both the propensity-score-adjusted risks of mechanical ventilation and death after mechanical ventilation were not significantly different in the HC group (aHR, 1.19; 95% CI, 0.78-1.82; p = 0.42 and aHR, 2.11; 95% CI, 0.96-4.62; p = 0.06, respectively) or in the HC+AZ group (aHR, 1.09; 95% CI, 0.72-1.66; p = 0.69 and aHR, 1.25; 95% CI, 0.59-2.68; p = 0.56, respectively) compared to the no HC group.

Conclusions: Among patients hospitalized with COVID-19, this retrospective study did not identify any significant reduction in mortality or in the need for mechanical ventilation with hydroxychloroquine treatment with or without azithromycin.

Funding: University of Virginia Strategic Investment Fund.

Keywords: COVID-19; SARS-CoV-2; azithromycin; hazard ratio; hydroxychloroquine; mortality; retrospective cohort; ventilation.

PubMed Disclaimer

Conflict of interest statement

J.A. is a co-founder of iVeena Holdings, iVeena Delivery Systems, and Inflammasome Therapeutics; he has received consultancy fees from Allergan, Biogen, Boehringer Ingelheim, Immunovant, Janssen, Olix Pharmaceuticals, Retinal Solutions, and Saksin LifeSciences, all for ophthalmic topics unrelated to COVID-19. J.A. is named as an inventor on a patent application filed by the University of Virginia relating to COVID-19 but unrelated to this work or to any ongoing COVID-19 clinical trials. S.S.S. has received research grants from Boehringer Ingelheim, Gilead Sciences, Portola Pharmaceuticals, and United Therapeutics, all for projects unrelated to COVID-19. J.W.H. has received consulting fees from Celgene Corporation unrelated to this work. The other authors declare no competing interests.

Figures
Graphical abstract

Graphical abstract
Graphical abstract
Figure 1

Distribution of Treatment Cohorts in…

Figure 1

Distribution of Treatment Cohorts in the Full Study Cohort of 807 Hospitalized COVID-19…

Figure 1

Distribution of Treatment Cohorts in the Full Study Cohort of 807 Hospitalized COVID-19 Patients AZ, azithromycin; CI, confidence interval; HC, hydroxychloroquine;

Update of

Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. Magagnoli J, Narendran S, Pereira F, Cummings T, Hardin JW, Sutton SS, Ambati J. Magagnoli J, et al. medRxiv [Preprint]. 2020 Apr 21:2020.04.16.20065920. doi: 10.1101/2020.04.16.20065920. medRxiv. 2020. PMID: 32511622 Free PMC article. Updated. Preprint.